Press Releases

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

PsychoGenics Awarded an NIH Contract to Test and Identify Novel Therapeutics for Pain

PsychoGenics Inc. Awarded $3 million SBIR Grant to Employ its AI-enabled Platforms to Find Treatments for Rare Disorders

Filters

Filters

Therapeutic Areas

Specific Disorders

Filters

PsychoGenics Awarded an NIH Contract to Test and Identify Novel Therapeutics for Pain

PsychoGenics Inc. Awarded $3 million SBIR Grant to Employ its AI-enabled Platforms to Find Treatments for Rare Disorders

Unlock New Possibilities with PsychoGenics’ Special Offer!

PsychoGenics Achieves Top Supplier Status on Scientist.com for 2023

PsychoGenics Announces Exclusive Global License for an IND-ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders

PsychoGenics Launches Updated Corporate Identity and Brand

PsychoGenics and Collaborations Pharmaceuticals Awarded a $1M grant to Use AI Platforms to Design New Drugs for Mental Health Disorders

PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics

PsychoGenics Strengthens Executive Team to Boost CNS Drug Discovery and CRO Capabilities

Let’s Find the Right Solution Together

Quick Links

Contact

Address

Email

Phone

Fax